- Home
- PLX vs MOLN Comparison
PLX vs MOLN Comparison
Compare PLX & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLX | MOLN |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.1M | 147.5M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PLX | MOLN |
|---|---|---|
| Price | $2.55 | $3.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.36 |
| AVG Volume (30 Days) | ★ 840.6K | 1.9K |
| Earning Date | 08-12-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $52,744,000.00 | N/A |
| Revenue This Year | $55.77 | N/A |
| Revenue Next Year | N/A | $450.00 |
| P/E Ratio | $9.57 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.65 | $3.52 |
| 52 Week High | $3.19 | $5.36 |
Technical Indicators
Market Signals| Indicator | PLX | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 42.21 | 39.53 |
| Support Level | $2.21 | N/A |
| Resistance Level | $2.75 | $4.21 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 7.41 | 15.12 |
Price Performance
Historical ComparisonAbout PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.